Close Menu

Natera

The company expects to launch Signatera for clinical use in colorectal cancer next year and has started to recruit a sales team for the assay.

A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.  

 

The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.

Of the 29 companies in the index, 18 companies' share prices declined while the share values of 11 increased month over month.

If the underwriters exercise their option to purchase the over-allotment in full, total gross proceeds from the offering would be $230 million.

The company said it processed around 200,000 tests in the third quarter, representing approximately 20 percent growth over the year-ago quarter.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

According to Natera CEO Steve Chapman, the agreement will not detract from Natera's own efforts to establish its exome sequencing-based Signatera assay.

The companies will use Foundation Medicine's FoundationOne CDx test as the baseline to define a set of unique variants that the codeveloped assays will monitor.

The company published a quality assurance study for the Panorama test last month and is wrapping up the SMART study, which has enrolled 20,000 women.

Pages